A comprehensive review says the success of semaglutide and tirzepatide is not just about weight loss but signals a paradigm shift in how metabolic disease is approached.
Tag: GLP-1
Ozempic and Wegovy Linked to a Surprising Drop in Impulsive Violent Behavior — Rutgers Study
GLP-1 receptor agonists like semaglutide appear to weaken the link between impulsive tendencies and violent behavior opening a potential new application in mental health.
Opinion: Why GLP-1 Sales Haven’t Taken Off Despite Enormous Potential — Zerodha’s Kamath Wonders Too
Zerodha co-founder Nikhil Kamath takes to X to question why obesity drugs like Ozempic are still underperforming in India despite strong international buzz.
Ozempic and GLP-1 Drugs Linked to 30% Lower Breast Cancer Risk in Large Study
A major new study finds that women taking Ozempic Wegovy Mounjaro and Zepbound are about 30% less likely to develop breast cancer.
New Oral GLP-1 Medication Shows Dramatic Blood Sugar and Weight Loss in Major Clinical Trial
A landmark trial reveals an oral version of GLP-1 medication dramatically improves blood sugar control and drives significant weight loss in type 2 diabetes.
The New GLP-1 Pill Could Be a Diabetes Game-Changer — But Who Will Afford It?
Opinion on the promise and pricing challenges of a new oral GLP-1 medication that dramatically improves blood sugar in clinical trials.
Ozempic and GLP-1 Drugs Linked to 30 Percent Lower Breast Cancer Risk in Major Study
A large study found that women taking GLP-1 drugs like Ozempic and Wegovy were approximately 30 percent less likely to develop breast cancer.
Five Ways the GLP-1 Revolution Is Changing How We Think About Obesity Treatment
A health writer examined how the growing body of evidence on GLP-1 drugs is forcing doctors and policymakers to rethink obesity as a metabolic disease rather than a lifestyle choice.
Ozempic and Wegovy Weight Loss Plateau Explained by Different Brain Cell Responses Says NIH
New NIH research revealed why GLP-1 receptor agonists eventually stop working by showing that appetite-regulating neurons respond differently over time.
GLP-1 Drugs at Lower Doses Shown to Maintain Weight Loss Outcomes in New Trials
Two clinical trials found that reduced doses of GLP-1 weight-loss medications and newer oral pills like Foundayo can maintain weight loss outcomes lowering costs and side effects.